作者: David Standring , April L. Patty , Maria Seifer , Jean-Pierre Sommadossi
DOI:
关键词:
摘要: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided includes administering β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester prodrug. In addition, preventing mutation from occurring naive and/or suppressing the emergence of double mutant (L528M/M552V) also